MAUNA KEA TECHNOLOGIES SECURES AN EQUITY FINANCING FACILITY PARIS, March 12th 2015 - Mauna Kea Technologies (Euronext: MKEA; ISIN: FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today announced the implementation of an equity financing facility with Société Générale, based on the 20th resolution approved by the General Meeting of Shareholders of June 11, 2014.

At the current share price1, the facility would provide a maximum capital contribution to the Company of €7 million. Proceeds from the facility will enhanced Mauna Kea Technologies' cash balance (€15 million as of December 31, 2014) and will be used to support its commercialization efforts.
Under this equity financing facility, and subject to certain conditions, Société Générale has committed itself to subscribing 1,390,000 new shares (representing 9.9% of current capital) over the course of the next ten months, at its own pace and timing. If the financing facility were to be used in full, and considering the fact the company has the ability to stop the equity financing at anytime, a shareholder with 1% of the capital today would see that holding drop to 0.91% of capital2.
For each tranche, the issuing price will be at a discount of 5% with respect to the volume weighted average price of the last three trading days. Société Générale does not intend to remain a holder of the Company's capital, so the discount will allow it to guarantee the share subscription in spite of possible volatility of the financial markets.
The Company will release the number of shares issued under this equity line every month.

"We are pleased that this facility can further boost the Company's cash balance, thereby supporting the ongoing global commercialization efforts for our unique Cellvizio platform. Our goal is to implement this plan in a manner that minimizes the dilution of our shareholders while positioning the Company for sustained growth." said Sacha Loiseau, Founder and Chief Executive Officer of Mauna Kea

Technologies.

1 5,28 euros at the closing price on March 12th, 2015

2 On the basis of 13,992,519 shares that make up Mauna Kea Technologies' capital on the date of this press release.


About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on leading innovation in endomicroscopy and optical biopsy. The company designs, develops and markets innovative tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. The company's flagship product, Cellvizio®, a probe- based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers with high-resolution cellular imaging of internal tissues. Large- scale, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians to more accurately detect early forms of diseases and make immediate treatment decisions. Designed to help physicians in their diagnoses, provide patients with better treatment and reduce hospital costs, the Cellvizio system can be used with practically all endoscopes. Cellvizio has 510(k) clearance from the United States Food and Drug Administration and CE Marking in the European Union for use in the gastrointestinal tract and the urinary and respiratory systems, for endoscopic exploration of the biliary and pancreatic ducts, and for fine-needle aspiration procedures. Cellvizio also obtained SFDA regulatory approval in China and MHLW approval in Japan.

For further information on Mauna Kea Technologies, visit www.maunakeatech.com

Mauna Kea Technologies

Eric Cohen

Vice President Finance

Tel: +33 (0)1 70 08 09 70


investor-vpf@maunakeatech.com

France and Europe

NewCap

Investor Relations & Financial Communication

Florent Alba / Pierre Laurent

Tel: +33 (0)1 44 71 94 94


maunakea@newcap.fr

U nite d S tate s

Berry & Company Public Relations

US - Public Relations

Bill Berry

Tel: +1 212 253 8881

bberry@ber ryp r.com

distributed by